NCT03577704View on ClinicalTrials.gov

The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 8, 2018

Primary Completion Date

September 30, 2022

Study Completion Date

December 30, 2022

Conditions
Advanced Solid Tumors
Interventions
DRUG

HLX07+Gemcitabine+Cisplatin

"Recombinant anti-EGFR humanized monoclonal antibody in combination with Gemcitabine and Cisplatin.~HLX07, IV, weekly."

DRUG

HLX07+Paclitaxel+Carboplatin

"Recombinant anti-EGFR humanized monoclonal antibody in combination with Paclitaxel and Carboplatin.~HLX07, IV, weekly."

DRUG

HLX07+mFOLFOX6

"Recombinant anti-EGFR humanized monoclonal antibody in combination with Oxaliplatin, Calcium Folinate and 5-FU.~HLX07, IV, weekly."

Trial Locations (1)

200123

Shanghai East Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Henlius Biotech

INDUSTRY

NCT03577704 - The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors. | Biotech Hunter | Biotech Hunter